Log In Sign up
The largest database of trusted experimental protocols

Simcyp version 18

Manufactured by Certara
Visit Supplier
Sourced in United States

Simcyp, version 18, is a physiologically-based pharmacokinetic (PBPK) modeling and simulation platform. It provides a comprehensive framework for predicting the absorption, distribution, metabolism, and excretion (ADME) of drugs in virtual populations.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

Simcyp (8 citations)

2 protocols using simcyp version 18

1

PBPK Modeling of HCQ and DHCQ

Check if the same lab product or an alternative is used in the 5 most similar protocols
A previously published PBPK model (Simcyp, version 18; Certara USA) was used as the base model for our studies (Table S1, referred to as “base model” throughout the article).12 The base model was developed to support HCQ dosing regimens for treatment of COVID‐19. For the current analysis, the PBPK model used to simulate the concentration versus time profiles of HCQ and DHCQ in SARS‐CoV‐2 (−)/(+) populations was developed in Simcyp version 21.
Steinbronn C., Chhonker Y.S., Stewart J., Leingang H., Heller K.B., Krows M.L., Paasche‐Orlow M., Bershteyn A., Stankiewicz Karita H.C., Agrawal V., Laufer M., Landovitz R., Wener M., Murry D.J., Johnston C., Barnabas R.V, & Arnold S.L. (2023). A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2(−)/(+) populations. Clinical and Translational Science, 16(7), 1243-1257.
+ Open protocol
+ Expand
2

Pediatric Tadalafil Dose Prediction

Check if the same lab product or an alternative is used in the 5 most similar protocols
The model of tadalafil disposition in adults was developed and applied to pediatric populations in Simcyp version 18 (Certara, Princeton, NJ). The Simcyp Healthy Volunteer and Pediatric Populations were used in adult and pediatric simulations, respectively. All simulations were conducted using a fixed seed value of 1, and where coefficient of variation was an input, the value was 30%. The approach to developing the PBPK model to predict doses of tadalafil in young children (<2 years old) is depicted in Figure 1.
Rehmel J., Ferguson‐Sells L., Morse B.L., Li B, & Dickinson G.L. (2021). Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension. CPT: Pharmacometrics & Systems Pharmacology, 11(2), 173-184.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!